Bronchiectasis management in adults: state of the art and future directions
European Respiratory Journal · 2024-06 · 63 (6) · 2400518
DOI: 10.1183/13993003.00518-2024 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Respiratory Journal, online erschienen am 23.05.2024. Verfasst von Hayoung Choi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Hallym U…. Hauptthemen laut MEDLINE: Bronchiectasis, Anti-Bacterial Agents, Quality of Life, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 124-mal zitiert (Crossref) und nennt 146 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Formerly regarded as a rare disease, bronchiectasis is increasingly recognised. A renewed interest in this disease has led to significant progress in bronchiectasis research. Randomised clinical trials (RCTs) have demonstrated the benefits of airway clearance techniques, inhaled antibiotics and long-term macrolide therapy in bronchiectasis patients. However, the heterogeneity of bronchiectasis remains one of the most challenging aspects of management. Phenotypes and endotypes of bronchiectasis have been identified to help find “treatable traits” and partially overcome disease complexity. The goals of therapy for bronchiectasis are to reduce the symptom burden, improve quality of life, reduce exacerbations and prevent disease progression. We review the pharmacological and non-pharmacological treatments that can improve mucociliary clearance, reduce airway inflammation and tackle airway infection, the key pathophysiological features of bronchiectasis. There are also promising treatments in development for the management of bronchiectasis, including novel anti-inflammatory therapies. This review provides a critical update on the management of bronchiectasis focusing on treatable traits and recent RCTs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Republic of Korea.
- Division of Pulmonary and Critical Care, University of Texas Health Science Center at Tyler, Tyler, TX, USA.
- Department of Biomedical Sciences, Humanitas University, Milan, Italy.
- Respiratory Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
- Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK jchalmers@dundee.ac.uk.
ORCID-Profile: Hayoung Choi, Stefano Aliberti, James D Chalmers
Zitieren
APA
Choi, H., McShane, P. J., Aliberti, S., & Chalmers, J. D. (2024). Bronchiectasis management in adults: state of the art and future directions. European Respiratory Journal, 63(6), 2400518. https://doi.org/10.1183/13993003.00518-2024
Vancouver
Choi H, McShane PJ, Aliberti S, Chalmers JD. Bronchiectasis management in adults: state of the art and future directions. European Respiratory Journal. 2024;63(6):2400518. doi:10.1183/13993003.00518-2024
BibTeX
@article{Choi2024,
author = {Choi, Hayoung and McShane, Pamela J and Aliberti, Stefano and Chalmers, James D},
title = {Bronchiectasis management in adults: state of the art and future directions},
journal = {European Respiratory Journal},
year = {2024},
volume = {63},
number = {6},
pages = {2400518},
doi = {10.1183/13993003.00518-2024}
}
EUVIMED